CT P24
Alternative Names: CT-P24Latest Information Update: 28 Apr 2021
At a glance
- Originator Celltrion
- Developer Celltrion; Valneva; Yonsei University Health System
- Class Antibodies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Hepatitis B
Most Recent Events
- 28 Apr 2021 No recent reports of development identified for research development in Hepatitis-B(Treatment-resistant) in South Korea
- 28 Mar 2018 No recent reports of development identified for research development in Hepatitis-B(Treatment-resistant) in South Korea
- 16 Mar 2016 Early research development is ongoing in South Korea (Celltrion pipeline, March 2016)